Neprilysin

抑制剂选择性比较

Neprilysin产品

所有产品(3) Neprilysin抑制剂(3)

目录号	产品描述	文献引用	实验数据
S3388	Sacubitrilat Sacubitrilat (Sac, LBQ-657) 是一种 neprilysin (NEP) 的活性抑制剂。
S7678	Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan)，由valsartan和sacubitril以1：1的摩尔比组成，是一个口服生物有效，双重作用的angiotensin receptor-neprilysin inhibitor (ARNi)，用于治疗高血压和心脏衰竭。Phase 3。	Arch Toxicol, 2022, 96(4):1065-1074 Cardiovasc Res, 2021, 117(5):1391-1401 Neurotox Res, 2021, 10.1007/s12640-021-00414-1	Histological analysis staining of three groups. (a) Representative H&E-staining micrographs displaying transverse myocardial section (original magnification ×200). (b) Masson staining of three groups (original magnification ×200). Collagen content (%) of heart tissues were presented as fibrosis (**P < 0.001, n = 7 per group). (c) Cardiac section of three group mice hearts stained with WGA (original magnification ×400) (P < 0.05, n = 7 per group). (d) The expression of Drp1 significantly increased in DOX group (*P < 0.001, n = 7 per group) and it decreased in DOX + LCZ696 group (P < 0.01, n = 7 per group).
S4426	Sacubitril hemicalcium salt Sacubitril (AHU-377) hemicalcium salt 是心力衰竭药物LCZ696的组成部分，一种有效的 neprilysin (neutral endopeptidase, NEP) 抑制剂。

目录号

产品描述

文献引用

实验数据

S3388

Sacubitrilat

Sacubitrilat (Sac, LBQ-657) 是一种 neprilysin (NEP) 的活性抑制剂。

S7678

Sacubitril/valsartan (LCZ696)

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan)，由valsartan和sacubitril以1：1的摩尔比组成，是一个口服生物有效，双重作用的angiotensin receptor-neprilysin inhibitor (ARNi)，用于治疗高血压和心脏衰竭。Phase 3。

Arch Toxicol, 2022, 96(4):1065-1074

Cardiovasc Res, 2021, 117(5):1391-1401

Neurotox Res, 2021, 10.1007/s12640-021-00414-1

S4426

Sacubitril hemicalcium salt

Sacubitril (AHU-377) hemicalcium salt 是心力衰竭药物LCZ696的组成部分，一种有效的 neprilysin (neutral endopeptidase, NEP) 抑制剂。

目录号	产品描述	文献引用	实验数据
S3388	Sacubitrilat Sacubitrilat (Sac, LBQ-657) 是一种 neprilysin (NEP) 的活性抑制剂。
S7678	Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan)，由valsartan和sacubitril以1：1的摩尔比组成，是一个口服生物有效，双重作用的angiotensin receptor-neprilysin inhibitor (ARNi)，用于治疗高血压和心脏衰竭。Phase 3。	Arch Toxicol,2022, 96(4):1065-1074 Cardiovasc Res,2021, 117(5):1391-1401 Neurotox Res,2021, 10.1007/s12640-021-00414-1	Histological analysis staining of three groups. (a) Representative H&E-staining micrographs displaying transverse myocardial section (original magnification ×200). (b) Masson staining of three groups (original magnification ×200). Collagen content (%) of heart tissues were presented as fibrosis (**P < 0.001, n = 7 per group). (c) Cardiac section of three group mice hearts stained with WGA (original magnification ×400) (P < 0.05, n = 7 per group). (d) The expression of Drp1 significantly increased in DOX group (*P < 0.001, n = 7 per group) and it decreased in DOX + LCZ696 group (P < 0.01, n = 7 per group).
S4426	Sacubitril hemicalcium salt Sacubitril (AHU-377) hemicalcium salt 是心力衰竭药物LCZ696的组成部分，一种有效的 neprilysin (neutral endopeptidase, NEP) 抑制剂。

目录号

产品描述

文献引用

实验数据

S3388